A mevalonate-independent pathway of isoprenoid biosynthesis present in Plasmodium falciparum was shown to represent an effective target for chemotherapy of malaria. This pathway includes 1-deoxy-D-xylulose 5-phosphate (DOXP) as a key metabolite. The presence of two genes encoding the enzymes DOXP synthase and DOXP reductoisomerase suggests that isoprenoid biosynthesis in P. falciparum depends on the DOXP pathway. This pathway is probably located in the apicoplast. The recombinant P. falciparum DOXP reductoisomerase was inhibited by fosmidomycin and its derivative, FR-900098. Both drugs suppressed the in vitro growth of multidrug-resistant P. falciparum strains. After therapy with these drugs, mice infected with the rodent malaria parasite P. vinckei were cured.
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Malaria is one of the leading causes of morbidity and mortality in the tropics, with 300 million to 500 million estimated clinical cases and 1.5 million to 2.7 million deaths per year. Nearly all fatal cases are caused by Plasmodium falciparum. Because the parasite's resistance to conventional antimalarial drugs such as chloroquine is growing at an alarming rate, new efficient drugs are urgently needed.
In all organisms studied so far, the biosynthesis of isoprenoids such as sterols and ubiquinones depends on the condensation of different numbers of isopentenyl diphosphate units (1) . In mammals and in fungi, isopentenyl diphosphate is derived from the mevalonate pathway. This pathway depends on the condensation of three molecules of acetyl coenzyme A (acetyl CoA) into 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), which is reduced to mevalonate by HMGCoA reductase. Mevalonate is further converted into isopentenyl diphosphate with mevalonate 5-phosphate as an intermediate. Previous studies revealed very low HMG-CoA reductase activity in P. falciparum (2) , and attempts to establish HMG-CoA reductase inhibitors as antimalarial drugs failed (3) , suggesting the absence of a mevalonate pathway in P. falciparum.
Recently, in some eubacteria, algae, and plants, the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway was described as an alternative nonmevalonate pathway for the early steps in the biosynthesis of isoprenoids. In higher plants, plastidic isoprenoids such as carotenoids are formed through the DOXP pathway (4) . The sterols, in turn, are formed in the cytosol through the mevalonate pathway. The DOXP pathway is characterized by the condensation of glyceraldehyde 3-phosphate and pyruvate to DOXP and its conversion to 2-C-methyl-D-erythritol 4-phosphate by the enzymes DOXP synthase and DOXP reductoisomerase (5, 6) . Searching for genes encoding enzymes of the DOXP pathway in P. falciparum, we identified similarities between known bacterial and blue algal protein sequences of the enzyme DOXP reductoisomerase and sequences on chromosome 14 of P. falciparum, obtained from the P. falciparum genome project (7). The high degree of similarity suggests the existence of a functional DOXP reductoisomerase in P. falciparum. The complete gene encoding the DOXP reductoisomerase of P. falciparum was consequently cloned (Fig. 1 ). In addition, we identified a P. falciparum gene that was very similar to the DOXP synthase of different species of bacteria and plants. Expression of these genes in the erythrocytic stages of P. falciparum (the stage responsible for the clinical manifesta- Fig. 1 . Alignment of the deduced amino acid sequence of the P. falciparum DOXP reductoisomerase with sequences from the homologous enzymes from other organisms (18). Pfal, P. falciparum (GenBank accession number AF1118131); Ecol, E. coli (GenBank accession number AF035440 and Swiss-Prot accession number P45568); Bsub, Bacillus subtilis (EMBL accession number Z99112); Syne, Synechocystis sp. PCC6803 (Swiss-Prot accession numbers P73067 and Q55663). Black and gray outlines indicate identical and similar amino acid residues, respectively. tion of the disease) was confirmed by reverse transcriptase-polymerase chain reaction (8).
In contrast to the protein sequences of the DOXP reductoisomerases from bacteria and blue algae, a unique NH 2 -terminal extension of the corresponding homologous enzyme of P. falciparum was identified (Fig. 1) . The first 30 amino acids of the NH 2 -terminal extension of the P. falciparum DOXP reductoisomerase resemble an endoplasmic reticulum signal peptide, whereas the following 44 amino acids exhibit the characteristics of plastidial targeting sequences (9). Because Toxoplasma gondii, in contrast to P. falciparum, can be transfected efficiently by means of established vectors, we transfected T. gondii with a construct containing the NH 2 -terminal sequence of the P. falciparum DOXP reductoisomerase fused to green fluorescent protein (GFP) (10). GFP accumulated in a restricted region of the cell that colocalizes with extranuclear apicoplast DNA (Fig. 2) . The apicoplast is a plastidlike organelle acquired by members of the phylum Apicomplexa by secondary endosymbiosis of an alga. The metabolic function of the apicoplast is not known, but it is essential for the survival of the parasites (11).
Recombinant P. falciparum DOXP reductoisomerase was produced in Escherichia coli (Fig. 3A) (12). The conversion of DOXP to 2-C-methyl-D-erythritol 4-phosphate by the recombinant enzyme was determined in an assay based on the NADPH (the reduced form of nicotinamide adenine dinucleotide phosphate) dependency of the reaction. This conversion was inhibited by fosmidomycin and its derivative, FR-900098, in a dosedependent manner (Fig. 3B) (Fig. 4) . Three P. falciparum strains with different sensitivity patterns to chloroquine and pyrimethamine were efficiently inhibited (Table 1) .
Because the DOXP pathway is absent in mammals and fosmidomycin and FR-900098 are known to have low toxicity (lethal doses of Ͼ8000 and Ͼ5000 mg/kg after oral and subcutaneous administration, respectively, in rats), their antimalarial activity was tested in an animal model (13). Mice infected with the rodent malaria parasite P. vinckei, which is fatal if untreated, were treated with the drugs from day 1 after infection to 4 days later (16). The drugs were well tolerated, even at the highest dosage of 300 mg/kg. Untreated control animals developed parasitemias of Ͼ60% on day 5 and died on day 7 after infection. Animals treated intraperitoneally with dosages of Ͼ10 mg/kg of fosmidomycin or 5 mg/ kg of FR-900098 were apparently free of parasites (Table 2 ). After treatment with 2 mg/kg of FR-900098 or 5 mg/kg of fosmidomycin, parasitemias were Ͻ1%. Animals treated orally with 50 or 100 mg/kg of either fosmidomycin or FR-900098 were apparently free of parasites, and parasitemias were Ͻ1% after treatment with 20 mg/kg of either drug. Recrudescence was observed when the treat- Fig. 2 . Targeting of GFP to the apicoplast of T. gondii by the leader peptide of the P. falciparum DOXP reductoisomerase. Toxoplasma gondii cells were transiently transfected with a construct encoding the leader peptide fused to the NH 2 -terminus of GFP. The localization of GFP was analyzed by direct fluorescence (green). Nuclear and apicoplast DNA were counterstained with 4Ј,6Ј-diamidino-2-phenylindole (blue). Color images were (left and middle) obtained independently and (right) overlaid. In summary, we provide evidence for the presence of the DOXP pathway in the apicoplast of P. falciparum and for the inhibition of one of the key enzymes of this pathway, DOXP reductoisomerase, with fosmidomycin and FR-900089. In addition, we have demonstrated the antimalarial activity of these drugs in vitro and in vivo. In former studies with volunteers and patients suffering from bacterial infections, fosmidomycin was well tolerated (17). The efficacy of these drugs against multidrug-resistant parasites and their low manufacturing costs and high stability make them very attractive as a potential new class of antimalarial drugs. (18) at the COOH-terminus. Bacteria ( Top10FЈ, Invitrogen) harboring this construct were induced for 4 hours with 1 mM isopropyl-␤-D-thiogalactopyranoside and disintegrated by sonication in buffer A [100 mM NaCl, 10 mM tris-HCl, and 2 mM 2-mercaptoethanol (pH 8.0)]. The enzyme was purified from the soluble fraction by affinity chromatography on Talon Superflow resin (Clontech, Heidelberg, Germany) with a highperformance liquid chromatography device (Gynkotek, Germering, Germany). The column was washed successively with 4 and 50 mM imidazole in buffer A. The protein was eluted with 100 mM imidazole in buffer A, resulting in a purity of ϳ80% as determined by SDSpolyacrylamide gel electrophoresis (SDS-PAGE). The enzymatic activity of the recombinant DOXP reductoisomerase was determined in 100 mM tris-HCl (pH 7.5), 1 mM MnCl 2 , 0.3 mM NADPH, and 1 mM DOXP while the oxidation of NADPH in a spectrophotometer at 365 nm was monitored. The specific activity of P. falciparum DOXP reductoisomerase was 6 U/mg as compared to 41 U/mg of DOXP reductoisomerase from E. coli. Escherichia coli DOXP reductoisomerase was overexpressed with a pQE9 vector (Qiagen). DOXP as substrate for the enzyme assay was enzymatically synthesized as described in (5) with the recombinant DOXP synthase from E. coli . The identity of DOXP was confirmed by 13 C nuclear magnetic resonance spectroscopy. 13. Fosmidomycin [3-(N-formyl-N-hydroxyamino) 1 (1998) ]. Three P. falciparum strains were used for the sensitivity test (HB3, Honduras; A2, The Gambia; and Dd2, Indochina). 16. The in vivo antimalarial activity was determined in P.
vinckei-infected mice with a modified 4-day suppressive test as described in work by Peters [W. Peters, Malaria, J. P. Kreier, Ed. (Academic Press, New York, 1980), vol. 1, pp. 160 -161]. Mice were intraperitoneally inoculated with 10 7 infected erythrocytes on day 0. On day 1, successful infection was confirmed, and the treatment was started. The drugs were administrated every 8 hours, three times per day, with respect to their short plasma half-life time as previously published [T. Murakawa, H. Sakamoto, S. Functional Interaction of BRCA1-Associated BARD1 with Polyadenylation Factor CstF-50 Frida E. Kleiman and James L. Manley* Polyadenylation of messenger RNA precursors requires a complex protein machinery that is closely integrated with the even more complex transcriptional apparatus. Here a polyadenylation factor, CstF-50 (cleavage stimulation factor), is shown to interact in vitro and in intact cells with a nuclear protein of previously unknown function, BRCA1-associated RING domain protein (BARD1). The BARD1-CstF-50 interaction inhibits polyadenylation in vitro. BARD1, like CstF-50, also interacts with RNA polymerase II. These results indicate that BARD1-mediated inhibition of polyadenylation may prevent inappropriate RNA processing during transcription, perhaps at sites of DNA repair, and they reveal an unanticipated integration of diverse nuclear events.
Almost all eukaryotic mRNAs have a polyadenylated [poly(A)] tail at the 3Ј end. Formation of this structure involves endonucleolytic cleavage of the mRNA precursor coupled with poly(A) synthesis, a reaction that requires a complex set of protein factors (1) . Although polyadenylation can be reconstituted in vitro with purified components and a synthetic mRNA precursor, considerable evidence now exists that, in the cell nucleus, 3Ј end formation is normally tightly coupled to transcription by RNA polymerase II (RNAP II). Polyadenylation factors associate with RNAP II at the promoter (2) and appear to remain with it during elongation (3). When RNAP II reaches the site of polyadenylation, it participates directly in the processing reaction together with the other polyadenylation factors (4); it also receives a signal needed for subsequent transcription termination (5) . How these complex interactions are orchestrated is not known. However, polyadenylation can be regulated, for example, during the cell cycle (6) and cellular differentiation (7).
Cleavage stimulation factor (CstF) is a polyadenylation factor that helps specify the site of processing (8, 9) . It is a heterotrimeric protein with subunits of 77, 64, and 50 kD that recognizes the GϩU-rich element, a sequence located downstream of the cleavage site. RNA binding is mediated by . CstF-77, or Suppressor-of-forked in Drosophila, bridges and interacts with another multisubunit factor, the AAUAAA-binding cleavage-polyadenylation specificity factor (CPSF), to define the poly(A) site (12). CstF-50 contains seven WD-40 repeats (13), is required for CstF activity in vitro (11), and interacts with the COOH-terminal domain of the RNAP II largest subunit (CTD) (3) .
To identify additional CstF-50 -interacting proteins, we performed a yeast two-hybrid assay (14); for bait we used CstF-50 fused to the LexA DNA binding domain (15). Among the strongest interacters recovered was BARD1 (16), a protein known to associate with the breast cancer-associated tumor suppressor BRCA1 in vivo. Both BARD1 and BRCA1 possess NH 2 -terminal RING motifs and COOH-terminal BRCT domains, with the former responsible for the . Although the function of BARD1 is unknown, inhibiting its expression in cultured cells results in changes that suggest a premalignant phenotype (18). BARD1 likely plays a role in BRCA1-mediated tumor suppression and may itself be a target for tumorigenic mutations in some cancers (19). BARD1, in association with BRCA1, can colocalize with the DNA replication and repair factors PCNA and Rad51, perhaps participating in the cellular response to DNA damage (20).
The BARD1 cDNAs obtained from the two-hybrid screen encoded amino acids 457 to 777 (Fig. 1A) , which includes two of three ankyrin repeats and the BRCT domain. We used essentially full-length BARD1 (amino acid residues 13 to 777), which interacted as efficiently as the smaller fragment, to confirm the interaction in yeast. CstF-50 (amino acid residues 92 to 431), which lacks the NH 2 -terminal region of CstF-50, also interacted strongly with BARD1. As observed with BRCA1 (21), yeast strains expressing BARD1 displayed a slow-growth phenotype (22).
We next characterized the BARD1-CstF-50 interaction in vitro. The two proteins were translated separately in vitro, mixed, and subjected to immunoprecipitation with antibodies to BARD1 (anti-BARD1 antibodies) (23) (Fig.  2A) . CstF-50 was precipitated in the presence (lane 3), but not in the absence (lane 2), of BARD1, which strongly suggests a specific interaction between the two proteins. In another approach, a glutathione S-transferase (GST)-BARD1 fusion protein (BARD1 residues 13 to 777) was purified from Escherichia coli and used in protein interaction assays, again with in vitro translated CstF-50 (Fig. 2B) . A significant fraction of the input CstF-50 bound to GST-BARD1 (lane 3) but not to GST alone (lane 2). COOH-terminal truncations of CstF-50 (see Fig. 1B ) eliminated binding (lanes 4 to 7), consistent with the requirement of at least the seventh WD-40 repeat for interaction. To elucidate the region of BARD1 required, we used additional GST-BARD1 derivatives (Fig. 1B ) in binding assays with CstF-50 (Fig. 2C) . A COOH-terminal truncation removing most of Department of Biological Sciences, Columbia University, New York, NY 10027, USA. *To whom correspondence should be addressed. Email: jlm2@columbia.edu 
